Deucrictibant not checked

Pharvaris Netherlands B.V. · PHA-022121 · PHA121

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
7 in total · 6 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use”In the company’s words, NCT07266805 on ClinicalTrials.gov
Tested for
Hereditary Angioedema (HAE) (2 trials), Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency and 10 more
Main trialPhase 3
“This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.”In the company’s words, NCT07266805 on ClinicalTrials.gov
Other names
PHA-022121 · PHA121 · PHVS416

Other drugs for Hereditary Angioedema (HAE)

All 8 drugs for Hereditary Angioedema (HAE)

Coming up3

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jun 2027 Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
Phase 3Enrolling by invitation 19 Aug 2031 Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Phase 2/3Enrolling by invitation Jun 2027 Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Phase 3Completed 17 Oct 2025 Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Phase 3Completed 21 Jul 2026 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Phase 2Completed 23 Sep 2022 Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Phase 2Terminated 30 Jun 2025 Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Deucrictibant

Following is part of Solo: you see every change to Deucrictibant the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in